Alzheimer’s Disease
Commission authorises medicine for treatment of early Alzheimer's disease
The Commission has granted EU authorization for Leqembi, a medicine to treat mild cognitive impairment in the early stages of Alzheimer's disease, under strict conditions. It is the first such medicine to be authorized in the EU.
This medicine is for use in people who have only one or no copy of the ApoE4 gene and who have amyloid beta plaques in the brain.
The authorisation is based on the positive scientific assessment of the European Medicines Agency, which concluded that the benefits of this medicine outweighed the risks, in a particular population of patients with such disease and as long as risk minimisation measures are applied. Therefore, the authorisation decision also sets strict conditions on the use of Leqembi, as well as clear risk mitigation requirements.
Share this article:
EU Reporter publishes articles from a variety of outside sources which express a wide range of viewpoints. The positions taken in these articles are not necessarily those of EU Reporter. Please see EU Reporter’s full Terms and Conditions of publication for more information EU Reporter embraces artificial intelligence as a tool to enhance journalistic quality, efficiency, and accessibility, while maintaining strict human editorial oversight, ethical standards, and transparency in all AI-assisted content. Please see EU Reporter’s full A.I. Policy for more information.
Kazakhstan cuts water use by 874 mln m³ through new technologies
Impasse in European Union Tobacco Tax Reform: The Swedish veto
Inconvenient questions about Andorra and San Marino that Brussels should be asking
How digital wallets are changing the way Welsh consumers pay for online services
Serbia’s business environment is driving its integration into the EU
Record breaking Belgian sailors making more waves
Europe's peripheral and maritime regions 'combine many territorial assets', meeting told
Message to Kemi Badenoch: 'Make a splash by thinking out-of-the-box on UK-Europe relationship'
'I don’t think Jews have a place neither in France nor in Belgium’, says Israeli deputy foreign minister
Ireland’s Presidency of the EU will link health and competitiveness
Western investors eye Russian assets again as sanctions discounts persist
EU green jobs: Which activities employ the most people?
Podcast: The story behind data on hazardous chemicals
EU's labour productivity slightly increased in Q1 2026
Government gross debt of eurozone largely in euro
Commission calls for equal pay rules to become a reality across the EU
Kazakhstan reforms under scrutiny at Brussels Press Club round table
Japan should face up to history and contribute more to regional peace
Ambassador calls for 'speeding up' of co-operation between EU and Kazakhstan
Timur Turlov at Smart Moves Summit 2025: How chess can transform global education
Shevtsova’s case: Out-of-court sanctions dismantling trust in Ukrainian cause
The future of European transport
Trump Vs Trueman
US 'no longer' an 'unconditional ally' for Europe - MEP
-
Kazakhstan3 days agoKazakhstan cuts water use by 874 mln m³ through new technologies
-
Health5 days agoImpasse in European Union Tobacco Tax Reform: The Swedish veto
-
San Marino5 days agoInconvenient questions about Andorra and San Marino that Brussels should be asking
-
General5 days agoHow digital wallets are changing the way Welsh consumers pay for online services